Cory Renauer
Value, research analyst, biotech, small-cap

Cerus Corp.'s Intercept Blood System Progress Report

Platelets, plasma, and red blood cells

Since its inception in 1991, Concord, California's Cerus Corporation (NASDAQ:CERS) has focused nearly all of its resources into the development of the Intercept Blood System. Donated blood undergoes intense screening for every conceivable pathogen before separated into red blood cells [RBCs], plasma, platelets, and numerous other products. The Intercept Blood System is intended to stop the proliferation of any pathogens that pass the screening process, or find their way into blood products during the manufacturing process.

Stops all gene expression, just add light

Cerus's Intercept Plasma and Platelet Systems are based on amotosalen HCL, a synthetic version of naturally occurring compounds that insert themselves into DNA. When exposed to ultraviolet radiation amotosalen...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details